ESMO 2023 – Perla gives Jemperli combos more backing
The numerical survival benefit versus Keytruda underperform’s Merck’s phase 3 study, but there’s a possible reason for that.
ESMO 2023 – Lumakras still looks like a colorectal also-ran
And first data with a low dose are particularly unimpressive.
ESMO 2023 – butterflies for J&J
Rybrevant underwhelms in Mariposa, handing a possible advantage back to AstraZeneca’s Tagrisso.
ESMO 2023 – some Tropion fears allayed
However, lack of meaningful efficacy in Tropion-Lung01 suggests that datopotamab deruxtecan might be restricted to a histology-defined NSCLC subgroup.
ESMO 2023 – tarlatamab hits the target for Amgen
But late-breaking data raise questions about lack of a dose response.
